The unique global resource at the heart of the drive for safer use of medicines

What is VigiBase?

VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme. The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified as rapidly as possible.

VigiBase is the unique WHO global database of individual case safety reports (ICSRs). It is the largest database of its kind in the world, with over 20 million reports of suspected adverse effects of medicines, submitted, since 1968, by member countries of the WHO Programme for International Drug Monitoring. It is continuously updated with incoming reports.

Alongside its data management and quality assurance tools, the VigiBase system is linked to medical and drug classifications such as WHO-ARTMedDRA, WHO ICD, and WHODrug. These classifications enable structured data entry, retrieval and analysis at different levels of precision and aggregation, which are vital in order to enable effective and accurate analysis.

Covering 90% of the world

UMC has developed and maintained VigiBase, the WHO global database of individual case safety reports (ICSRs), since 1978. Following the ten founder members of the late 60s, over 130 countries have now joined the WHO Programme, in all representing over 90% of the world’s population.

Read more about VigiBase

VigiBase FAQ


Read more